FMP

FMP

Enter

BNOX - Bionomics Limited

Financial Summary of Bionomics Limited(BNOX), Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug can

photo-url-https://financialmodelingprep.com/image-stock/BNOX.png

Bionomics Limited

BNOX

NASDAQ

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

0.902 USD

-0.0296 (-3.28%)

About

ceo

Dr. Spyridon Papapetropoulos M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.bionomics.com.au

exchange

NASDAQ

Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a ...

CIK

0001191070

ISIN

US09063M2052

CUSIP

09063M205

Address

200 Greenhill Road

Phone

61 8 8354 6100

Country

AU

Employee

8

IPO Date

Dec 16, 2021

Summary

CIK

0001191070

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

09063M205

ISIN

US09063M2052

Country

AU

Price

0.9

Beta

-0.08

Volume Avg.

95.22k

Market Cap

9.65M

Shares

-

52-Week

0.84-6.41

DCF

0.76

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.44

P/B

-

Website

https://www.bionomics.com.au

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BNOX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep